Acura shares tank on forecasted FDA delay

Acura Pharma shareholders were not the least bit happy to hear the developer announce yesterday that it was unlikely the FDA will approve Acurox--which combines niacin and oxycodone--by a June 30 deadline. Its shares tanked on the news, plunging more than 30 percent. Acura did not offer a reason why it believes the FDA won't make its deadline. "It's a data and labelling issue. I don't think they have the data to have an appropriate label," Biologic Investment Research analyst Kevin McNamara told ReutersReport

Suggested Articles

Pfizer’s 2017 spin-out company SpringWorks has lost president and founder Lara Sullivan, M.D. who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.

In our EuroBiotech roundup this week, Pfizer Ventures backs ImmunOs, Genmab shares cancer data and Newron delays readout.